The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Global Stocks Hit By Yuan Devaluation

Wed, 12th Aug 2015 16:11

LONDON (Alliance News) - Stocks across Europe ended lower Wednesday, while Wall Street remained in negative territory at the London close, after Chinese authorities devalued the yuan for the second time in as many days, with the pound regaining ground lost after a disappointing UK jobs report.

The FTSE 100 index ended down 1.4% at 6,571.19 points, and the FTSE 250 finished down 1.3% at 17,438.09, meaning it is the second consecutive negative close for both indices. The AIM-All Share shed 0.8% at 748.62.

However, London held up better than other European stock markets. The CAC 40 in Paris ended down 3.4%, and the DAX 30 in Frankfurt fell 3.3%.

At the European equities markets close, US stocks also were trading lower, with the Dow 30 down 1.3% and the S&P 500 and Nasdaq Composite both down 1.1%.

The sell-off of global stocks came after China's central bank cut its reference rate for a second time Wednesday following its surprise reduction on Tuesday. The People's Bank of China on Wednesday adjusted its daily reference exchange rate by a further 1.6%, setting it at 6.3306 to the US dollar. The central bank had devalued the yuan by 1.9% on Tuesday. The dollar traded the yuan at CNY6.3836 late Wednesday, having hit a four-year high at CNY6.4374 earlier in the day.

Addressing market concerns Wednesday, China's central bank said there was no basis for a sustained depreciation of the yuan given international and domestic economic conditions. The PBoC had said on Tuesday that the devaluation was a one-time adjustment.

The International Monetary Fund said Beijing's move to devalue the yuan was "a welcome step", to allow market forces to have a greater role in determining the exchange rate. Similarly, the European Commission also said the move was a "positive development".

But some analysts were concerned that the Chinese devaluation to support its exports could spark a currency war, with countries trying to hold onto their share of global exports.

"In isolation, currency devaluation improves global competitiveness, but if what follows are further rounds of devaluations from competing economies, then a currency war may begin; and this is rarely a force for good in the global economy," said Brewin Dolphin Head of Fund Research Ben Gutteridge.

Nevertheless, Standard & Poor's Ratings Services welcomed the Chinese move, saying it will not trigger a currency war.

"The argument that China is trying to spur growth by weakening its currency to spur exports does not strike us as very convincing," said Standard & Poor's chief economist for Asia-Pacific, Paul Gruenwald. "Exports are more a function of foreign demand, with the exchange rate playing a secondary role. There is no reason for that relationship to have changed."

Societe Generale analyst Aneta Markowska said the move by Chinese authorities means that a September interest rate hike by the US Federal Reserve is now a closer call. The analyst noted that China's decision to devalue the yuan will not only add deflationary pressures but could also have a negligible impact on the US growth.

"The move has the potential of delaying the Fed if it triggers capital outflows out of China and other emerging countries. The Fed wants to engineer a smooth lift-off and will be very sensitive to financial conditions at the time of the September meeting. We stick with our call for a September lift-off, but acknowledge that that it has become a closer call," Markowska said.

The yuan devaluation put the spotlight on quarterly results from US-listed Chinese e-commerce giant Alibaba Group. The company on Wednesday reported a sharp increase in its first-quarter profit, helped by a disposal gain. Revenue increased to 20.245 billion yuan, or USD3.265 billion, from 15.771 billion yuan in the previous year. Wall Street expected revenue of USD3.39 billion for the quarter, however. The company also announced a share buyback. The stock is down 30% since its initial public offering in September last year.

In London, the devaluation again hit mining stocks, as China is the largest consumer of metals, and other exporters to China. Glencore led the FTSE 100 fallers, down 5.7%, hitting a new all-time low during trade, while Anglo American fell 1.9%. Meanwhile, shares of Burberry Group, a luxury goods retailer with significant sales in China, lost 3.5%.

Investors shifted to gold, the traditional safe-haven asset, amid concerns about China, sending the price of the precious metal higher. Gold traded at USD1,124.18 an ounce late Wednesday. As a result, gold miners benefited, with Randgold Resources up 5.4% and Fresnillo up 0.1%.

FTSE 250 gold miner Centamin rose 11%, helped by the rise in gold prices but also by a set of positive results in which it reported a rise in its pretax profit in the first half of 2015, leading the company to increase its interim dividend by 11%. It said pretax profit for the first half of 2015 was USD47.4 million, up from USD31.9 million a year earlier, as revenue climbed to USD259.7 million from USD205.3 million. Centamin raised its interim dividend to 0.97 cents per share from 0.87 cents a year earlier.

Elsewhere, Unilever shares lost 4.3% after Goldman Sachs downgraded it to Sell from Neutral, while International Consolidated Airlines Group fell 4.4% after Kepler Cheuvreux cut the British Airways owner to Hold from Buy.

Zoopla Property Group added 3.9%. The property portal, which competes with Rightmove and which has recently faced the launch of a new player in the form of agency-back OnTheMarket, said it added 213 net new branches to its UK agency membership in the period from April 1 to July 31, returning to growth after having taken a hit from the launch of OnTheMarket. Zoopla added that the uSwitch price comparison business has continued to trade well since being acquired, with a particular boost from the energy switching market and a supportive regulatory environment for the energy business.

Meanwhile, the pound recovered after being hit following a somewhat weak UK jobs report. The UK unemployment rate was 5.6% for the three months to June, compared to 5.5% in three months to March, though down notably from 6.3% in the same period of last year. There were 1.85 million unemployed people in April to June, 25,000 more than in January to March period, data from the Office for National Statistics showed.

Average earnings including bonuses increased 2.4% from last year, missing expectations of a 2.8% rise following a 3.2% rise in the three months to May. Excluding bonus, pay climbed 2.8%, in line with estimates.

More positively, UK jobless claims declined unexpectedly in July. The number of people claiming unemployment benefits declined by 4,900 in July from June, while it was expected to rise by 1,000. The claimant count rate held steady at 2.3% as expected by economists.

The pound fell sharply against the dollar, hitting a low of USD1.5536 after the data. However, sterling recovered and was standing at USD1.5649 when the London stock market closed.

In the economic calendar Thursday, the German and French consumer price indices are due at 0700 BST and 0745 BST, respectively. In the US, retail sales and initial and continuing jobless claims are all expected at 1330 BST. US Business inventories are expected at 1500 BST.

In the UK corporate calendar, Coca-Cola HBC releases half-year results, TUI Group publishes third-quarter results, and Glencore releases its half-year production report. Infinis Energy and Grainger issue interim management statements, while Cineworld Group, Michael Page International, Derwent London and Ophir Energy and Promethean World publish half-year results.

Also Thursday, blue-chips as Fresnillo, Rio Tinto, Diageo, BG Group, BT Group, GlaxoSmithKline and Pearson, among many other London-listed companies, go ex-dividend, meaning new buyers no longer qualify for the latest dividend payout.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.